November – The year 2015 is set to go down as the biggest ever in terms of acquisitions deals as pharma giant Pfizer (NYSE: PFE) and Botox-maker Allergan (NYSE: AGN) set out to create the largest drug company in the world. Valued at $160 billion, the deal comes close on the heels of Pfizer’s $17 billion acquisition of Hospira and a failed attempt to grab UK drug major AstraZeneca (LSE: AZN).
The total deal vale for the year so far has touched $3.29 trillion, ahead of the $3.27 trillion recorded for the full-year 2014, according to data from Mergermarket. Given the pace of M&A activity it may not be wrong to estimate the year is likely to surpass the record deal value of $3.67 trillion witnessed in the year 2007.
Overall, a series of other big ticket deals in the pharma/biotech sector has marked the year as the strongest period of mergers and acquisition activity.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze